Format

Send to

Choose Destination
See comment in PubMed Commons below
Chest. 2013 Jul;144(1):160-168. doi: 10.1378/chest.12-2417.

Functional class improvement and 3-year survival outcomes in patients with pulmonary arterial hypertension in the REVEAL Registry.

Author information

1
Columbia University College of Physicians and Surgeons, New York, NY.
2
Stanford University School of Medicine, Stanford, CA; Palo Alto VA Health Care System, Palo Alto, CA.
3
Vera Moulton Wall Center for Pulmonary Vascular Disease, Stanford, CA.
4
ICON Late Phase & Outcomes Research, San Francisco, CA.
5
Mayo Clinic, Rochester, MN. Electronic address: mmcgoon@mayo.edu.

Abstract

OBJECTIVE:

New York Heart Association/World Health Organization functional class (FC) is associated with outcomes in pulmonary arterial hypertension (PAH). We assessed whether patients with PAH who improve from FC III to FC I/II have improved survival vs patients who remain at FC III or worsen to FC IV.

METHODS:

Patients aged ≥ 19 years with FC III PAH from the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL Registry) (N = 982) were categorized as improved, unchanged, or worsened according to their change in FC from enrollment to first follow-up assessment within 1 year of enrollment. Kaplan-Meier estimates of 3-year survival from first follow-up and changes in 6-min walk distance (6MWD) from enrollment to first follow-up were determined. Subgroup analyses were conducted by cause (ie, idiopathic/familial, connective tissue disease [CTD], congenital heart disease) and time of diagnosis (ie, newly or previously diagnosed [diagnostic right-sided heart catheterization within or ≥3 months of enrollment, respectively]).

RESULTS:

Overall, 27% of patients improved FC. Survival was better in patients whose FC improved (84%±2%, n=263) vs those who remained unchanged (66%±2%, n=645) or worsened (29%±6%, n=74) (all P<.001). Survival was also better in patient subgroups whose FC improved vs those who remained unchanged (idiopathic/familial [P<.001], CTD-associated PAH [P=.009], whether newly [P=.004] or previously diagnosed [P<.001]). 6MWD improvements were greater in patients whose FC improved vs those who remained unchanged in the overall (P<.001) and CTD (P=.028) cohorts.

CONCLUSION:

Patients with PAH who improve from FC III to I/II, whether newly or previously diagnosed and regardless of PAH cause, have better survival vs patients who remain FC III.

TRIAL REGISTRY:

ClinicalTrials.gov; No.: NCT00370214; URL: www.clinicaltrials.gov.

PMID:
23429998
DOI:
10.1378/chest.12-2417
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center